Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
495 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS, Brown DM, Chong V, et al. · Ophthalmology · 2012Clinical Trial, Phase III, Comparative Study
- Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.
Campochiaro PA, Avery R, Brown DM, et al. · Lancet · 2024Clinical Trial, Phase I, Clinical Trial, Phase II
- Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration.
Cheung CMG, Lim JI, Priglinger S, et al. · Ophthalmology · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Dietary Nutrient Intake and Progression to Late Age-Related Macular Degeneration in the Age-Related Eye Disease Studies 1 and 2.
Agrón E, Mares J, Clemons TE, et al. · Ophthalmology · 2021Clinical Trial, Phase III, Multicenter Study
- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, et al. · Ophthalmology · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- The Mediterranean Diet and Age-Related Eye Diseases: A Systematic Review.
Wu Y, Xie Y, Yuan Y, et al. · Nutrients · 2023Systematic Review
- Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future.
Colijn JM, Buitendijk GHS, Prokofyeva E, et al. · Ophthalmology · 2017Meta-Analysis
- Comparative outcomes of aflibercept biosimilars and reference aflibercept in nAMD: a systematic review and meta-analysis.
Sawires K, Nithianandan H, Somani S · BMJ Open Ophthalmol · 2025Systematic Review, Meta-Analysis
- One-year outcome of neovascular age-related macular degeneration patients followed-up using different optical coherence tomography modalities.
Sukkarieh G, Vasseur V, Lejoyeux R, et al. · Eur J Ophthalmol · 2022Randomized Controlled Trial
- Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response.
Chaudhary V, Brent M, Lam WC, et al. · Ophthalmologica · 2016Multicenter Study, Randomized Controlled Trial
- Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis.
Samacá-Samacá D, Hernández-Castillo C, Prieto-Pinto L, et al. · BMJ Open Ophthalmol · 2024Systematic Review, Network Meta-Analysis
- Safe CNV removal is crucial for successful hESC-RPE transplantation in wet age-related macular degeneration.
Lv YX, Li QY, Duan P, et al. · Stem Cell Reports · 2025Clinical Trial, Research Support, Non-U.S. Gov't
- Radiotherapy for neovascular age-related macular degeneration.
Evans JR, Igwe C, Jackson TL, et al. · Cochrane Database Syst Rev · 2020Meta-Analysis, Research Support, Non-U.S. Gov't
- Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial.
Fan W, Abdelfattah NS, Uji A, et al. · Graefes Arch Clin Exp Ophthalmol · 2018Multicenter Study, Randomized Controlled Trial
- Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration.
London NJS, Cheung CMG, Michels S, et al. · Ophthalmol Retina · 2025Clinical Trial, Phase III, Equivalence Trial
- Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
Low A, Faridi A, Bhavsar KV, et al. · Br J Ophthalmol · 2019Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S.
- Prospective evaluation of aflibercept in pigment epithelial detachments secondary to neovascular age related macular degeneration.
Diaconita V, Li B, Pal L, et al. · Can J Ophthalmol · 2019Randomized Controlled Trial
- Home-monitoring for neovascular age-related macular degeneration in older adults within the UK: the MONARCH diagnostic accuracy study.
Hogg RE, Wickens R, O'Connor S, et al. · Health Technol Assess · 2024Systematic Review, Research Support, Non-U.S. Gov't
- The Association between Retinal Thickness Fluctuations and Visual Outcomes under Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-Analysis.
Pandya B, Mihalache A, Hatamnejad A, et al. · Ophthalmologica · 2024Systematic Review, Meta-Analysis
- Association of Genetic Variants with Polypoidal Choroidal Vasculopathy: A Systematic Review and Updated Meta-analysis.
Ma L, Li Z, Liu K, et al. · Ophthalmology · 2015Meta-Analysis, Systematic Review
- Genetic associations in polypoidal choroidal vasculopathy: a systematic review and meta-analysis.
Chen H, Liu K, Chen LJ, et al. · Mol Vis · 2012Meta-Analysis, Research Support, Non-U.S. Gov't
- Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
Sadda SR, Tuomi LL, Ding B, et al. · Ophthalmology · 2018Clinical Trial, Phase III, Multicenter Study
- Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis.
Rosenberg D, Deonarain DM, Gould J, et al. · Eye (Lond) · 2023Meta-Analysis, Systematic Review
- INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results.
de Oliveira Dias JR, Costa de Andrade G, Kniggendorf VF, et al. · Retina · 2019Clinical Trial
- Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis.
Nichani PAH, Popovic MM, Mihalache A, et al. · Ophthalmologica · 2024Meta-Analysis, Systematic Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.